Market Overview

Nektar Hit With Double Downgrade From Goldman: 'Significant Challenges In Rebuilding Confidence'

Share:
Nektar Hit With Double Downgrade From Goldman: 'Significant Challenges In Rebuilding Confidence'

Nektar Therapeutics (NASDAQ: NKTR) has seen several setbacks in the near-term, including sagging revenues and a regulatory delay for its investigational opioid analgesic.

The Analyst

Goldman Sachs analyst Paul Choi downgraded Nektar from Buy to Sell and reduced the price target from $54 to $16. 

The Thesis

Nektar shares have underperformed over the past 18 months as execution missteps related to suboptimal batches of the multiple myeloma drug bempegaldesleukin overshadowed announcements of mostly positive clinical developments, Choi said in the Tuesday downgrade note. (See his track record here.) 

This has driven investor uncertainty over bempeg's safety or efficacy, shifting the focus to the company's ability to execute on a large-scale clinical development program, the analyst said. 

Notwithstanding the 60% downside in the stock since its Jan. 19 high, Choi said the uncertainty on both these points will likely continue to be an overhang.

"We believe NKTR now faces significant challenges in rebuilding confidence in the clinical and commercial outlook for bempeg + Opdivo, which we now believe will take several years longer than prior, opening opportunities for competitor drugs that have recently reported positive trial results." 

Citing negative clinician checks and the developmental plateauing of the broader I/O field, Goldman Sachs downgraded Nektar to Sell.

Near-term catalysts are unlikely to re-rate the stock in the face of quality issues and a narrower focus for bempeg, Choi said.

The Price Action

At last check, Nektar shares were sliding 10.93% to $16.63. 

Related Links:

The Daily Biotech Pulse: D-Day For Clinuvel, Qiagen Warns Of Q3 Shortfall, Prevail Announces Gene Therapy Collaboration

BioNTech IPO: What You Need To Know

Latest Ratings for NKTR

DateFirmActionFromTo
Nov 2019MaintainsNeutral
Nov 2019MaintainsBuy
Nov 2019MaintainsNeutral

View More Analyst Ratings for NKTR
View the Latest Analyst Ratings

Posted-In: Goldman Sachs Paul ChoiAnalyst Color Biotech Downgrades Price Target Analyst Ratings Trading Ideas

 

Related Articles (NKTR)

View Comments and Join the Discussion!

Latest Ratings

StockFirmActionPT
TORCCantor FitzgeraldDowngrades3.0
CIDMCanaccord GenuityMaintains1.5
TDGCanaccord GenuityMaintains620.0
DLPNCanaccord GenuityMaintains1.6
WBCLSADowngrades
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com

Option Trader Makes Big Bet On iQiyi Despite Negative Trade War Headlines

Everything You Need To Know About The Focus V Carta e-Rig For Cannabis Concentrates